ACON
BEARISH
$3.33
Live
Aclarion, Inc. · NASDAQ
Target $23.0
(+590.7%)
$2.34
52W Range
$31.05
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$3.51M
P/E
N/A
ROE
-97.7%
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
92%
ACON's deterministic health scores are severely compromised: the Piotroski F-Score of 1/9 signals extreme financial distress, and the absence of an Altman Z-Score (with negative profitability and liquidity anomalies) raises serious bankruptcy concerns. Despite a 31.5% YoY revenue growth, the company exhibits catastrophic profitability—negative gross, operating, and ROE margins—indicating fundamental operational failure. The stock trades at a price/sales of 52.03, vastly exceeding peers and suggesting extreme overvaluation relative to earnings. Analysts' target price of $23.00 is not supported by fundamentals, and insider activity remains neutral with no recent trades. The 5-year price decline of 100% underscores deep investor skepticism.
Key Strengths
31.5% year-over-year revenue growth indicates top-line expansion
High current and quick ratios (17.01 and 16.31) suggest strong short-term liquidity
Recent 1-month price increase (+22.9%) shows short-term momentum
One analyst coverage provides minimal market attention and potential for re-rating
Historical earnings surprise improvements (e.g., +34.8% in 2024-08-14) suggest possible operational stabilization
Key Risks
Piotroski F-Score of 1/9 indicates severe financial deterioration and poor operational health
Negative operating margin (-9666.16%) and ROE (-97.72%) reflect systemic profitability collapse
Price/Sales of 52.03 is unsustainable and far exceeds peer averages (avg: ~185.39 P/E, but negative margins suggest no valid comparison)
No free cash flow, operating cash flow, or dividend history—no return to investors
Analyst target price ($23.00) is 690% above current price ($3.33), implying extreme speculative optimism without fundamentals
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
14
Weak
15
35
10
12
0
AI Verdict
High Risk
Key drivers: Piotroski F-Score of 1/9, Negative profitability across all metrics, Extreme price-to-sales multiple, No cash flow generation, 5-year price collapse
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- High current and quick ratios suggest liquidity cushion
Watchpoints
- Price/Sales of 52.03 is extremely high for a company with negative earnings
- No Graham Number or intrinsic value available due to negative earnings and no sustainable growth
- No P/E or PEG ratios to anchor valuation
- Trading at 10x the 52-week low despite deteriorating fundamentals
Future
35/100
Ref Growth rates
Positives
- 31.5% YoY revenue growth suggests top-line momentum
- Recent earnings surprises have improved (e.g., +34.8% in 2024-08-14)
Watchpoints
- Earnings growth is not sustainable with negative margins and no cash flow
- Forward P/E of -0.24 indicates no earnings expectation
- No free cash flow to support future growth
- High revenue growth is not translating into profitability
Past
10/100
Ref Historical trends
Positives
- Historical revenue growth has been strong (e.g., 31.5% YoY)
- Some quarters showed positive earnings surprises
Watchpoints
- Consistently negative earnings with worsening margins over time
- EPS has declined sharply (e.g., -345.4% surprise in 2022-08-15)
- 5-year price return of -100% reflects persistent investor distrust
- No consistent earnings progression or profitability
Health
12/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High current and quick ratios (17.01, 16.31) indicate strong liquidity
Watchpoints
- Piotroski F-Score of 1/9 is the lowest possible, signaling extreme financial distress
- No Altman Z-Score available, but negative ROE, ROA, and operating margin suggest high bankruptcy risk
- Negative operating margin (-9666.16%) is unsustainable
- No debt/equity or cash/debt data, but liquidity appears inflated by non-operational factors
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield, payout ratio, or history
- Dividend Strength score of 0/100 confirms no dividend policy
- Negative earnings make dividend payment impossible
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.33
Analyst Target
$23.0
Upside/Downside
+590.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACON and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
Primary
|
-100.0% | -100.0% | -82.0% | -56.9% | +22.9% | +1.8% |
|
NUWE
Nuwellis, Inc.
Peer
|
-100.0% | -100.0% | -96.9% | -64.7% | +3.8% | +13.4% |
|
ISPC
iSpecimen Inc.
Peer
|
-99.9% | -99.5% | -89.9% | -85.3% | -46.7% | -9.9% |
|
MNDR
Mobile-health Network Solutions
Peer
|
-99.7% | -99.7% | -89.1% | -76.7% | -0.3% | -3.9% |
|
HCTI
Healthcare Triangle, Inc.
Peer
|
-100.0% | -100.0% | -99.9% | -98.6% | -21.6% | -2.8% |
ACO
Aclarion, Inc.
Primary
5Y
-100.0%
3Y
-100.0%
1Y
-82.0%
6M
-56.9%
1M
+22.9%
1W
+1.8%
NUW
Nuwellis, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-96.9%
6M
-64.7%
1M
+3.8%
1W
+13.4%
ISP
iSpecimen Inc.
Peer
5Y
-99.9%
3Y
-99.5%
1Y
-89.9%
6M
-85.3%
1M
-46.7%
1W
-9.9%
MND
Mobile-health Network Solutions
Peer
5Y
-99.7%
3Y
-99.7%
1Y
-89.1%
6M
-76.7%
1M
-0.3%
1W
-3.9%
HCT
Healthcare Triangle, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-99.9%
6M
-98.6%
1M
-21.6%
1W
-2.8%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.24
PEG Ratio
N/A
P/B Ratio
0.16
P/S Ratio
52.03
EV/Revenue
-135.51
EV/EBITDA
1.38
Market Cap
$3.51M
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-9666.16%
Gross Margin
-7.83%
ROE
-97.72%
ROA
-52.37%
Growth
Revenue and earnings growth rates
Revenue Growth
+31.5%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
17.01
Strong
Quick Ratio
16.31
Excellent
Cash/Share
$16.95
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-12
$-2.93
-11.0% surprise
2025-08-14
$-2.75
-21.6% surprise
2025-04-09
$-1628.09
-20.0% surprise
2024-11-14
$-1356.74
+16.7% surprise
Healthcare Sector Comparison
Comparing ACON against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-97.72%
This Stock
vs
-101.52%
Sector Avg
-3.7%
(Below Avg)
Revenue Growth
31.5%
This Stock
vs
124.21%
Sector Avg
-74.6%
(Slower)
Current Ratio
17.01
This Stock
vs
4.56
Sector Avg
+273.1%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACON
Aclarion, Inc.
|
BEARISH | $3.51M | - | -97.7% | -% | $3.33 | |
|
NUWE
Nuwellis, Inc.
|
BEARISH | $3.23M | - | -382.6% | -211.9% | $1.23 | Compare |
|
ISPC
iSpecimen Inc.
|
BEARISH | $3.8M | - | -327.8% | -% | $0.13 | Compare |
|
MNDR
Mobile-health Network Solutions
|
BEARISH | $3.07M | - | -47.6% | -35.3% | $0.84 | Compare |
|
HCTI
Healthcare Triangle, Inc.
|
BEARISH | $2.77M | - | -183.0% | -48.8% | $2.4 | Compare |
ACON
Aclarion, Inc.
BEARISH
Mkt Cap
$4M
P/E
-
ROE
-97.7%
Price
$3.33
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-11-26 | NESS BRENT | Chief Executive Officer | Purchase | 10 | $62 |
NESS BRENT
Chief Executive Officer
2025-11-26
10 shares
·
$62
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Ascendiant Capital
2025-11-20
Buy
Buy
Ascendiant Capital
2025-09-19
Buy
Buy
Past News Coverage
Recent headlines mentioning ACON from our newsroom.
Newest → oldest
No matching news yet.